ライフサイエンスコーパス: cross-presentation

1 both antigen-specific CD4+ and CD8+ T cells (cross-presentation).

2 rnalization, CD40, was the most efficient at cross presentation.

3 n to MHC class I molecules, a process termed cross presentation.

4 the two conformational states to potentiate cross-presentation.

5 ated C-type lectin receptors fail to promote cross-presentation.

6 f which contributes to the fine-tuning of Ag cross-presentation.

7 d tumor immunogenicity and optimized antigen cross-presentation.

8 d mediates the power of DC efferocytosis and cross-presentation.

9 role of oxidized lipids in the regulation of cross-presentation.

10 to elucidate the mechanisms of TLR2-mediated cross-presentation.

11 trols phagosomal pH, a critical parameter in cross-presentation.

12 --that mediates DC efferocytosis and antigen cross-presentation.

13 ulation of nonoxidized lipids did not affect cross-presentation.

14 ctive of T-cell receptor affinity or antigen cross-presentation.

15 ell immunity to these pathogens necessitates cross-presentation.

16 ate naive CD8(+) T cells in a process termed cross-presentation.

17 teasomal degradation products and blocked Ag cross-presentation.

18 ose of a less pure LPS preparation inhibited cross-presentation.

19 to pure LPS abrogated its ability to enhance cross-presentation.

20 s of DC maturation on MHC class I-restricted cross-presentation.

21 strong as those induced exclusively through cross-presentation.

22 ose virus strains that are most dependent on cross-presentation.

23 class I loading in a process referred to as cross-presentation.

24 tor specialized for delivery of antigens for cross-presentation.

25 from internalized proteins, a process called cross-presentation.

26 nological function in dendritic cell (DC) Ag cross-presentation.

27 h the cytosolic from the vacuolar pathway of cross-presentation.

28 re them with lymph node resident DCs through cross-presentation.

29 some recruitment and enhance TAP-independent cross-presentation.

30 us (IAV)-peptides following either direct or cross-presentation.

31 T cells, but in vivo immunity still requires cross-presentation.

32 mic reticulum-phagosome traffic required for cross-presentation.

33 DCs are responsible for antigen exchange and cross-presentation.

34 thereby optimizing XCR1(+) DC maturation and cross-presentation.

35 lpha(+) dendritic cells (DCs) in exosomal Ag cross-presentation.

36 o draining lymph nodes, and enhances antigen cross-presentation.

37 and captured stable proteins permissive for cross-presentation.

38 te defects in both CD8 T cell activation and cross-presentation.

39 lar milieu on MHC-I through a process called cross-presentation.

40 I (MHC-I) molecules are the centerpieces of cross-presentation.

41 st be deployed to deliver Ag to pDCs for Ag (cross-)presentation.

42 ient (FcgammaR quadruple(-/-)) mice, and the cross-presentation ability of CD8alpha(+) DCs was not af

43 e investigated the mechanisms underlying the cross-presentation ability of IFN-DCs by studying the in

44 fy4 (-/-) mice with known defects in antigen cross-presentation, accumulated in joint tissue and the

45 Cross-presentation allows antigen-presenting cells to pr

46 Cross-presentation allows dendritic cells (DCs) to prese

47 l phagocytosis subsequently enhances antigen cross-presentation and activation of cyclic GMP-AMP synt

48 +) DCs led to cytokine production and robust cross-presentation and activation of tumor antigen-speci

49 nt cell death pathways may affect neoepitope cross-presentation and Ag recognition of cancer cells.

50 We used cross-presentation and CD137 activation-based FACS to en

51 ype 1 dendritic cells that are essential for cross-presentation and CD8 T cell-mediated immunity agai

52 toxicity is desirable and even necessary for cross-presentation and cross-priming of T cells.

53 bulk large tumors, release tumor antigen for cross-presentation and cross-priming, release cancer-sup

54 Cross-presentation and crosspriming depend not only on T

55 ogel significantly enhanced antigen-specific cross-presentation and cytotoxic T lymphocyte (CTL) acti

56 ockade also potently suppressed both antigen cross-presentation and direct presentation of synthetic

57 organ-resident CD8(+) DCs are specialized at cross-presentation and have developed specific adaptatio

58 ings provide important insights into antigen cross-presentation and have implications for development

59 eeks of T cell-replete syngeneic HSCT led to cross-presentation and increased survival of lymphoma-be

60 istinct pathway that operates within DCs for cross-presentation and is required for the activation of

61 rmulations with peptide Ags stimulate strong cross-presentation and potent CD8 T cell responses assoc

62 are unique organ-resident APCs capable of Ag cross-presentation and subsequent tolerization of naive

63 TLR3 engagement in CD8(+) DCs promotes cross-presentation and the acquisition of effector funct

64 The enhanced antigen cross-presentation and the increased APC recruitment to

65 processing of dead cell-derived antigens for cross-presentation and the induction of effective CD8(+)

66 3(+) mDCs are presented by both MHC class I (cross-presentation) and MHC class II to antigen-specific

67 T-cell priming include direct presentation, cross-presentation, and cross-dressing.

68 cific T cells poorly, despite its long-lived cross-presentation, and T cells primed against the short

69 in TLR-induced dendritic cell activation and cross-presentation, and thus is vital in host defense.

70 or CD11c, BDCA1(+) DCs were as efficient at cross presentation as BDCA3(+) DCs.

71 Together, our data identify cross-presentation as a novel mechanism through which ce

72 riming and tumor rejection required tumor Ag cross-presentation, as evidenced by tumor outgrowth in K

73 wn as IFN-DCs, highly efficient in mediating cross-presentation, as well as the cross-priming of CD8(

74 This was probably due to promotion of cross-presentation because it was not detected when the

75 es IC uptake and is essentially required for cross-presentation, but not for MHC class II Ag presenta

76 n vitro scavenging of ROS partially restored cross-presentation by aged DCs.

77 lysaccharide and interferon-gamma as well as cross-presentation by bone marrow-derived dendritic cell

78 Moreover, no detectable Ag cross-presentation by CD8alpha(+) DCs from C1qa(-/-) mic

79 In this study, to examine cross-presentation by classical dendritic cells (DCs; cD

80 TLR-stimulated cross-presentation by conventional dendritic cells (cDCs

81 cell responses were attributed to increased cross-presentation by DCs along with increased detection

82 Consequently, U-Omp19 enhances Ag cross-presentation by DCs to CD8(+) T cells.

83 The contribution of antigen cross-presentation by DCs to the induction of anti-viral

84 ficking protein Rab39a is needed for optimal cross-presentation by dendritic cells in vitro and cross

85 educe IRAP-dependent but not ERAP1-dependent cross-presentation by dendritic cells with nanomolar eff

86 s and mediators, IgE-mediated tumour antigen cross-presentation by dendritic cells, as well as immuno

87 3(+) DCs and not BDCA-1(+) DCs show improved cross-presentation by FcgammaR targeting, as measured by

88 Modulation of cross-presentation by Ig was inhibited by coapplication

89 sociated with a marked inhibition in antigen cross-presentation by Igfbp7(-/-) dendritic cells.

90 ontrast to classical spleen dendritic cells, cross-presentation by liver antigen-presenting cells was

91 f HA-1 long peptide resulted in efficient Ag cross-presentation by mDCs and pDCs, leading to strong e

92 ning the tyrosine signal but does not affect cross-presentation by MHC-I containing the HLA-C cytopla

93 In APCs, we show that HIV Nef disrupts cross-presentation by MHC-I containing the tyrosine sign

94 in adaptor protein 1 (AP-1) is necessary for cross-presentation by MHC-I molecules containing a cytop

95 n contrast, AP-1 activity was not needed for cross-presentation by MHC-I molecules containing a human

96 We also studied LP cross-presentation by monocyte-derived DC, plasmacytoid

97 modified LP gave rise to high and sustained cross-presentation by monocyte-derived DC.

98 ntigen processing and MHC class I-restricted cross-presentation by reducing disulfide bonds of endocy

99 Oxidized lipids blocked cross-presentation by reducing the expression of peptide

100 Surprisingly, antigen cross-presentation by resident CX3CR1(+) DCs induced dif

101 oited by us to deliver viral epitopes, whose cross-presentation by the HLA-B27 molecules was proteaso

102 elopment or many primary infections requires cross-presentation by XCR1(+) dendritic cells (DCs).

103 y reveal that key steps of Ag processing for cross-presentation can be modulated by TLR ligands, open

104 Mouse XCR1(+) DC excel at cross-presentation, can be targeted in vivo to induce pr

105 C class I exogenous peptide presentation and cross-presentation capacities.

106 Taken together, their cross-presentation capacity and type I IFN production to

107 Despite dampened cross-presentation capacity, batf3(-/-) chimeras had equ

108 but not macrophages, display high intrinsic cross-presentation capacity.

109 er with adenovirus, a model for intrahepatic cross-presentation, confirms hepatocytes directly contri

110 rly demonstrate that CD8alpha(+) DC-mediated cross-presentation does not significantly contribute to

111 s I pathway; thus, it is widely assumed that cross-presentation drives the priming of antiviral T cel

112 somes with ERC-derived MHC-I, and subsequent cross-presentation during infection.

113 taining vesicles contributes to the superior cross-presentation efficacy of CD8(+) cDCs.

114 o distinct endocytic compartments determines cross presentation efficiency, possibly by influencing a

115 , to analyze Sec61's contribution to antigen cross-presentation, ERAD, and transport of internalized

116 DCs from these mice show impaired cross-presentation ex vivo and defective cross-priming o

117 Thus, the requirement of IRAP in cross-presentation extends to steady-state cDCs.

118 This selectivity does not extend to antigen cross-presentation for T-cell proliferation but is requi

119 The study of cross-presentation has been focused on the relative cont

120 h early and late endosomes appear to support cross presentation in human DCs, internalization efficie

121 Pretreatment with pure LPS increased cross-presentation in a manner dependent on both MyD88 a

122 V mutants to elucidate the pathway of capsid cross-presentation in AAV-permissive cells.

123 the spatiotemporal orchestration of antigen cross-presentation in antigen-presenting cells with inna

124 of spatio-temporal orchestration of antigen cross-presentation in antigen-presenting cells with inna

125 s a NE receptor that mediates uptake and PR1 cross-presentation in breast cancer cells.

126 is study demonstrates a mechanism regulating cross-presentation in cancer and suggests potential ther

127 We find that impaired cross-presentation in DCs is largely associated with def

128 We conclude that Sec22b-dependent cross-presentation in DCs is required to initiate CD8(+)

129 Although antigen cross-presentation in dendritic cells (DCs) is critical

130 enzyme that prepares antigenic epitopes for cross-presentation in dendritic cells, in complex with a

131 sion, strongly suggesting a role for in situ cross-presentation in local antigen-driven T(RM) differe

132 1 substrates is the cause of altered antigen cross-presentation in Sec61-blocked DCs.

133 ammaR) antigen targeting facilitates antigen cross-presentation in several DC subsets, including BDCA

134 the micelles significantly enhanced antigen cross-presentation in vitro relative to free ovalbumin,

135 ound that both combinations promoted antigen cross-presentation in vitro.

136 response by efficiently stimulating antigen cross-presentation in vivo and in vitro assessed by BMDC

137 dicating that Sec61 blockade affects antigen cross-presentation indirectly.

138 Cross-presentation is a critical function of dendritic c

139 Cross-presentation is a key function of dendritic cells

140 Cross-presentation is a modular series of intracellular

141 Cross-presentation is considered the primary mode of ant

142 In TAP-deficient mouse dendritic cells, cross-presentation is enhanced by the introduction of hu

143 Dendritic cell (DC) Ag cross-presentation is generally associated with immune r

144 Antiviral immunity and cross-presentation is mediated constitutively through CD

145 Moreover, inhibition of cross-presentation is neither due to reduced costimulato

146 Cross-presentation is one of the main features of dendri

147 leoprotein (NP)(366-374) presentation, while cross-presentation is optimal for acid polymerase (PA)(2

148 Cross-presentation is particularly effective with long s

149 ly contaminant responsible for shutting down cross-presentation is peptidoglycan (PGN).

150 vitro activation, suggesting that in humans cross-presentation is restricted to certain DC subsets.

151 We further showed that LP cross-presentation is restricted to monocytes and conven

152 response can be generated in a system where cross-presentation is shut down by pretreatment with CpG

153 However, how TLR triggering can affect Ag cross-presentation is still not clear.

154 of IAV-specific CD8 T cells, suggesting that cross-presentation is sufficient for cytotoxic T lymphoc

155 8(+) T cell epitope frequently used to study cross-presentation, is ATP-dependent but substantially T

156 ression of genes encoding elements of the Ag cross-presentation machinery (i.e., of proteasome matura

157 related markers on B cells and activated the cross-presentation machinery.

158 upport a previously unrecognized model of Ag cross-presentation mediated by HLA-F and MHC-I open conf

159 This increased E75 cross-presentation, mediated by trastuzumab treatment, e

160 ent HIV-1-derived Ags to CD8(+) T cells in a cross-presentation model, we investigated whether LCs we

161 aded onto MHC-I molecules, a process called "cross-presentation." Neither the actual contribution of

162 summary, our data suggest that TLR2-mediated cross-presentation occurs through the upregulation of Ra

163 As expected, BDCA3(+) DCs were superior at cross presentation of antigens delivered to late endosom

164 directly and quantitatively by comparing the cross presentation of identical antigens conjugated with

165 the FcR CD32 led to uptake, processing, and (cross-) presentation of encapsulated Ag to both CD4(+) a

166 eviously reported that the HLA-A2-restricted cross-presentation of a long peptide derived from melano

167 article, we show that the HLA-A1-restricted cross-presentation of a long peptide derived from tumor

168 ngle tumor released doxorubicin and enhanced cross-presentation of a model antigen at distant tumor s

169 ts with PEI/DNA complexes leads to efficient cross-presentation of a model antigen by dendritic cells

170 study shows that cDCs are indispensable for cross-presentation of ablation-released tumor antigens a

171 , persistence of virally infected cells, and cross-presentation of Ag.

172 dosomal/lysosomal compartments necessary for cross-presentation of Ag.

173 confirms hepatocytes directly contribute to cross-presentation of Ags and priming the pool of naive

174 They altered cross-presentation of Ags by dendritic cells to epitope-

175 Cross-presentation of Ags by osteoclasts leads to expres

176 An apparent cross-presentation of antigen acquired from muscle sugge

177 cells in wild-type animals was dependent on cross-presentation of antigen by cells of the tumor stro

178 ficantly more efficient lysosomal escape and cross-presentation of antigen from dendritic cells (DCs)

179 ty peptide-MHC interactions led to efficient cross-presentation of antigen, thereby stimulating cogna

180 e and readily processed soluble proteins for cross-presentation of antigenic peptides to CD8(+) T cel

181 duce virus-specific CD8+ T cells through the cross-presentation of antigens from virally infected cel

182 Finally, consistent with their defect in the cross-presentation of apoptotic cells, DC-specific Vps34

183 We investigate the mechanisms of cross-presentation of associated peptides and co-stimula

184 t aged murine DCs were less efficient in the cross-presentation of cell-associated Ag and subsequentl

185 ying cells by CD8alpha(+) dendritic cells or cross-presentation of cell-associated Ag to CD8(+) T cel

186 ent monocyte-derived DCs showed no defect in cross-presentation of cell-associated antigen.

187 s but show a defect for in vivo and in vitro cross-presentation of cell-associated antigen.

188 gest that DNGR-1 is a dedicated receptor for cross-presentation of cell-associated antigens.

189 causes the receptor to signal and potentiate cross-presentation of dead cell-associated antigens by D

190 actin exposed by dying cells and facilitates cross-presentation of dead cell-associated antigens by d

191 gand binding led to loss of DNGR-1-dependent cross-presentation of dead cell-associated antigens, for

192 cruits the tyrosine kinase Syk to promote DC cross-presentation of dead cell-associated antigens.

193 strength-dependent manner and that controls cross-presentation of dead cell-associated antigens.

194 41 is a negative regulator of Clec9A and the cross-presentation of dead cell-derived antigens by mous

195 om destructive to productive and facilitates cross-presentation of disease-relevant epitopes to CD8(+

196 DNGR-1 was essential for cross-presentation of dying vaccinia virus-infected (VAC

197 vitro, increased HER2 uptake by DC increased cross-presentation of E75, the immunodominant epitope de

198 pression as well as antigenic stimulation by cross-presentation of EBV antigen from destroyed B cells

199 ss-priming of CD8(+) T cells, which requires cross-presentation of exogenous Ag to DCs.

200 The effects of TLR triggering on the cross-presentation of exogenous Ags by DCs remain unclea

201 e for human pDCs as professional APCs in the cross-presentation of exogenous Ags is being re-evaluate

202 iated DCs, tumor-derived factors blocked the cross-presentation of exogenous Ags without inhibiting t

203 Activation markers, cross-presentation of exogenous Ags, and activation of C

204 Dendritic cell (DC)-mediated cross-presentation of exogenous antigens acquired in the

205 ptide to CD8(+) T cells occurs normally, but cross-presentation of GRP94/VSV8 complexes is defective.

206 Following cross-presentation of HSP-chaperoned peptides by CD91(+)

207 pDC are capable of classical presentation or cross-presentation of IAV antigens and could potentially

208 genous tumor-reactive CD8(+) T cells via the cross-presentation of IgG complexed antigens (IgG IC), a

209 Cross-presentation of IgG-containing immune complexes (I

210 nd DCs failed to have a strong effect on the cross-presentation of immune complex (IC) OVA Ag to CD8(

211 B-cell cross-presentation of insulin required proteolytic cleav

212 In this study, we show cross-presentation of islet-derived autoantigens by B ce

213 e involvement of the vacuolar pathway in the cross-presentation of long peptides, and indicate that T

214 nal dendritic (cDC1) cells are necessary for cross-presentation of many viral and tumor antigens to C

215 uble antigen, suggesting that processing and cross-presentation of nano-particulate antigen is favore

216 While cross-presentation of native OVA requires high antigen d

217 atf3-dependent dendritic cells specialize in cross-presentation of necrotic tissue-derived epitopes t

218 Moreover, MGL1-mediated cross-presentation of OVA-Le(X) neither required TAP-tra

219 C-I) presentation in dendritic cells enables cross-presentation of peptides derived from phagocytosed

220 Cross-presentation of phagocytosed Ags by MHC class I (M

221 e, the frequently reported TAP dependence of cross-presentation of phagocytosed OVA may principally r

222 n, including breast cancer, which results in cross-presentation of PR1, an NE-derived HLA-A2-restrict

223 Efficient cross-presentation of protein Ags to CTLs by dendritic c

224 eperfusion injury also promoted DC-dependent cross-presentation of renal antigens to CD8 T cells in t

225 IRAP deficiency compromised cross-presentation of soluble and particulate Ag by both

226 immunoglobulins (Ig) in vivo are impaired in cross-presentation of soluble antigen.

227 eral Ags to LECs, which maintain tolerogenic cross-presentation of such Ags.

228 n unrecognized tumor immune escape involving cross-presentation of systemically circulating tumor ant

229 as opposed to the HLA-A2-restricted peptide, cross-presentation of the HLA-A1-restricted peptide is T

230 c patients to MN-derived DCs (moDCs) induced cross-presentation of the intracellular reservoir of vir

231 The uptake and long-term cross-presentation of tumor Ag long peptides (LP) by den

232 s showed that NK cells inhibited DC-mediated cross-presentation of tumor Ags both in vivo and in vitr

233 s, stroma destruction, due to MHC-restricted cross-presentation of tumor antigens to T cells, may be

234 rs tumor cell autophagy and that it improves cross-presentation of tumor antigens to the immune syste

235 tment activated dendritic cells and enhanced cross-presentation of tumor-associated antigens to CD8 T

236 F1 in classical dendritic cells enhanced the cross-presentation of tumour antigens and the cross-prim

237 odies (Abs) that facilitated the capture and cross-presentation of viral Ags by FcgammaR-expressing D

238 cells are effectively primed against CPXV by cross-presentation of viral Ags in young mice.

239 non-redundant ability of DNGR-1 to regulate cross-presentation of viral antigens suggests that this

240 d inhibition of cathepsins markedly enhances cross-presentation of wild-type dendritic cells.

241 , Ags from immune complexes undergo enhanced cross-presentation on DC, leading to greater CD8 T cell

242 ntly acquires secreted mTEC-derived TRAs for cross-presentation on MHC-I.

243 OX2, previously recognized to participate in cross-presentation, on phagosomes, thereby filling in a

244 ear whether this reflects specialization for cross presentation or a generally enhanced ability to pr

245 the proteasome- and TAP-dependent cytosolic cross-presentation pathway, previously shown to be used

246 Thus, we provide evidence for two separable cross-presentation pathways, only one of which is target

247 iated with Ag processing-dependent auxiliary cross-presentation pathways.

248 T cell survival: that rather than utilizing cross-presentation, pDC must be infected and utilize the

249 sults support a model in which host tumor Ag cross-presentation primes adoptively transferred T cells

250 reas ROS interfered with a later step in the cross-presentation process.

251 The mechanisms of cross presentation remain incompletely understood, parti

252 We further show that PR1 cross-presentation renders human breast cancer and melan

253 FcgammaR-facilitated cross-presentation requires antigen processing in both a

254 Although cross-presentation requires Sec22b-mediated phagosomal r

255 cells) could offer the ideal environment for cross-presentation, resulting in cytotoxic immunity and

256 AB43 provides a specialized activity used in cross-presentation selectively by CD8alpha(+) DCs but no

257 Collectrin-mediated cross-presentation supports intrahepatic adaptive antivi

258 DCs are not likely to possess mechanisms for cross presentation that are specific to this subset.

259 gand annexin1 is an important mediator in DC cross-presentation that increases efferocytosis in DCs a

260 we unravel a novel pathway of MHC I-mediated cross-presentation that is initiated with a host cellula

261 1 (cDC1) subpopulation important for antigen cross-presentation, that CD40L-overexpressing CAR T cell

262 pressed on the subset of DCs responsible for cross-presentation, the CD8(+) murine splenic DCs.

263 Ag cross-presentation, the process by which pathogen Ags ar

264 Due to increased cross-presentation, these capped nanofibers trigger stro

265 Direct activation of DCs with PGN inhibited cross-presentation through nucleotide-binding oligomeriz

266 This synergy was dependent on TAA cross presentation to cytolytic CD8+ T cells and on IFN-

267 dendritic cells (DCs), and facilitate their cross presentation to stimulate an antitumor T-cell resp

268 ntation." Neither the actual contribution of cross-presentation to antitumor immune responses nor the

269 This facilitates its cross-presentation to autoaggressive cytotoxic MHC-E-res

270 to CD4 T cells but impacts the efficiency of cross-presentation to CD8 T cells.

271 splenic CD8(+) DCs in vitro, namely antigen cross-presentation to CD8(+) T cells and secretion of IL

272 gonist treatment of mice inhibits Ag protein cross-presentation to CD8(+) T cells but preserves their

273 p-deficient dendritic cells induce increased cross-presentation to CD8(+) T cells by activating Rac2

274 ve increased activation of Rac2 that support cross-presentation to CD8(+) T cells.

275 a recycling endosomal compartment, favoring cross-presentation to CD8(+) T cells.

276 both through MHC class II expression and in cross-presentation to CD8s.

277 ides locally generated by proteasomes allows cross-presentation to generate MHC-I-peptide complexes i

278 ude that the host uses mainly DCs capable of cross-presentation to induce the CMV-specific CD8(+) T c

279 f IgG ICs to the proper destination for such cross-presentation to occur.

280 alpha-DEC205, and alpha-Clec9A also mediated cross-presentation to primed CD8(+) T cells if, in paral

281 ellular pathways collectively referred to as cross-presentation to stimulate CD8(+) T cells with pept

282 40-48 epitope into productive processing and cross-presentation to strongly autoaggressive CTLs.

283 , as well as reduced immune complex-mediated cross-presentation to T cells.

284 the class I-mediated antigen processing and cross-presentation transcriptional modules that were not

285 t nucleated cells and exogenous proteins for cross-presentation typically by professional APCs.

286 Cross-presentation using splenic NOTAM DCs and prolonged

287 via alternative means, potentially including cross-presentation via the MHC class II pathway.

288 The decreased cross-presentation was associated with a reduction in th

289 e cytosol, suggesting that the inhibition of cross-presentation was not related to either of these tr

290 This cross-presentation was sensitive to inhibitors of lysoso

291 Apparently, this cross-presentation was TAP-independent, as it was conduc

292 To investigate how STAT2 affects cross-presentation, we determined its requirements for d

293 ome-dependent class I MHC-restricted peptide cross-presentation when delivered by alphaDEC205 in vitr

294 The intracellular pathway of cross-presentation, which allows MHC class I-restricted

295 lls (cDC1)(1) are thought to perform antigen cross-presentation, which is required to prime CD8(+) T

296 TNF stimulation augments LC cross-presentation while attenuating IRF4 expression.

297 The observed enhancement in OVA cross-presentation with polyU in DCs could be mediated b

298 In contrast, both classic and cross-presentation within MHC class I remain largely int

299 , which reactivate CTL by increasing antigen cross-presentation within the tumor microenvironment.

300 ccomplished through a pathway called antigen cross-presentation (XPT).